<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Although <z:mpath ids='MPATH_589'>dysplasia</z:mpath> is thought to be the precursor lesion in the development of <z:hpo ids='HP_0002583'>colitis</z:hpo>-associated <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>), a significant proportion of patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC) and low-grade (LGD) or indefinite (IND) <z:mpath ids='MPATH_589'>dysplasia</z:mpath> remain <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-free during endoscopic follow-up </plain></SENT>
<SENT sid="1" pm="."><plain>There is a need for biomarkers that predict <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We studied the value of a series of immunohistochemical markers in UC patients with flat LGD or IND with regard to <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Tissue samples were collected from 12 UC patients (six flat LGD, six IND) without progression and from 10 UC patients (eight flat LGD, two IND) with documented progression to HGD and/or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> during a median of 25 and 23 months of colonoscopic follow-up, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Immunohistochemistry using monoclonal antibodies was performed for p53, CD44, Ki67, AMACR, Î²-catenin, cyclin D1, p21, and ALDH </plain></SENT>
<SENT sid="5" pm="."><plain>Positive and negative staining patterns were compared for progression to advanced <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: When patients showed coexpression of p53 and AMACR, 6/7 patients (86%) developed advanced <z:hpo ids='HP_0002664'>neoplasia</z:hpo>, compared to 4/15 patients (27%) without p53/AMACR coexpression (P = 0.02) </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with p53/AMACR coexpression developed advanced <z:hpo ids='HP_0002664'>neoplasia</z:hpo> in a time period of 19 months (median, range 1-101) compared to 80 months (median, range 8-169) in patients without p53/AMACR coexpression (P = 0.14) </plain></SENT>
<SENT sid="8" pm="."><plain>Interestingly, in three patients with progression and previous <z:mpath ids='MPATH_589'>dysplasia</z:mpath>-negative biopsies, two out of three biopsies were p53-positive a median of 12 months (range 10-14) before the LGD/IND diagnosis </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: This study suggests a role for p53/AMACR coexpression as a potential marker of <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> in patients with UC </plain></SENT>
</text></document>